Lezárult
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.
2023-507705-34-00· 3. fázis· Alvotech Swiss AG· Forrás
Lezárult
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
NCT06534411· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A study to compare effectiveness and safety of a combination of vudalimab or pembrolizumab with chemotherapy in participants with advanced lung cancer.
NCT06173505· 1/2. fázis· Xencor Inc.· Forrás
Lezárult
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis
2023-506655-19-00· 2. fázis· Genentech Inc.· Forrás
Toboroz
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
2023-505775-70-00· 2. fázis· European Myeloma Network B.V.· Forrás
Fut, nem toboroz
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to
Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma
(RRMM)
2023-509472-42-00· 3. fázis· Celgene International II S.a.r.l.· Forrás
Fut, nem toboroz
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575· 2. fázis· Mirati Therapeutics Inc.· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· 2. fázis· Pfizer· Forrás
Lezárult
A clinical study of bemcentinib with standard of care chemoimmunotherapy in untreated advanced/metastatic non-small cell lung cancer patients with a mutation in the STK11 gene
NCT05469178· 1/2. fázis· Bergenbio ASA· Forrás
Lezárult
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)
2022-502057-33-00· 1/2. fázis· Sanofi-Aventis Recherche & Developpement· Forrás
Toboroz
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· 3. fázis· GlaxoSmithKline· Forrás
Lezárult
A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke
NCT05953480· 2. fázis· Shionogi· Forrás
Fut, nem toboroz
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05785767· 2/3. fázis· Regeneron Pharmaceuticals· Forrás
Lezárult
A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
2022-501451-87-00· 1/2. fázis· Zhejiang Genfleet Therapeutics Co. Ltd.· Forrás
Fut, nem toboroz
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke
NCT05643573· 3. fázis· Bayer AG· Forrás
Leállították
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05325866· 1/2. fázis· Amgen· Forrás
Lezárult
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide maintenance in Newly Diagnosed Patients with Multiple Myeloma and severe Renal Impairment
NCT05147493· 2. fázis· Hellenic Society Of Hematology· Forrás
Lezárult
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
NCT05350969· 2. fázis· Cardior Pharmaceuticals GmbH· Forrás
Lezárult
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
NCT05362058· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
NCT05298423· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
NCT05064358· 2. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973· 2. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
NCT05093933· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
NCT05021835· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
2023-509915-10-00· 1. fázis· Glaxosmithkline Research & Development Limited· Forrás
Fut, nem toboroz
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
NCT04793958· 3. fázis· Mirati Therapeutics Inc.· Forrás
Lezárult
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344· 3. fázis· Hoffmann-La Roche· Forrás
Lezárult
A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
NCT04617925· 2. fázis· Stichting European Myeloma Network· Forrás
Lezárult
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
NCT04463771· 2. fázis· Incyte Corporation· Forrás
Lezárult
Effectiveness of Wound Drains for the Prevention Of Surgical sITe infectION
NCT05179122· National and Kapodistrian University of Athens· Forrás
Lezárult
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT04475939· 3. fázis· GlaxoSmithKline· Forrás
Lezárult
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
NCT04489771· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet
NCT04191616· 2. fázis· Amgen· Forrás
Lezárult
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
NCT04221945· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
NCT04211337· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
NCT03989414· 1/2. fázis· Celgene· Forrás
Lezárult
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
NCT03872401· 3. fázis· Amgen· Forrás
Lezárult
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
NCT03900598· 1. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· 3. fázis· Tesaro, Inc.· Forrás
Lezárult
Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer
NCT03568097· 2. fázis· Hellenic Cooperative Oncology Group· Forrás
Fut, nem toboroz
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246· 3. fázis· pharmaand GmbH· Forrás
Lezárult
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
NCT03555422· 3. fázis· Karyopharm Therapeutics Inc· Forrás
Lezárult
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
NCT03201965· 3. fázis· Janssen Research & Development, LLC· Forrás
Lezárult
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
NCT03173560· 2. fázis· Eisai Inc.· Forrás
Lezárult
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03141177· 3. fázis· Bristol-Myers Squibb· Forrás
Lezárult
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
NCT02632409· 3. fázis· Bristol-Myers Squibb· Forrás